Regeneron Pharmaceuticals Inc. buy marge
Summary
This prediction ended on 23.11.21 with a price of €570.00. The BUY prediction by marge finished with a performance of 7.75%. marge has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | -3.175% | -3.175% | 11.571% | 100.644% |
iShares Core DAX® | -1.822% | -1.170% | 11.771% | 12.805% |
iShares Nasdaq 100 | -0.241% | 1.961% | 40.760% | 43.999% |
iShares Nikkei 225® | -2.310% | -1.758% | 21.493% | 2.467% |
iShares S&P 500 | -0.835% | 1.309% | 28.068% | 41.484% |
Comments by marge for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
(Der Cocktail war eine von drei pharmazeutischen Behandlungen, die Trump zur Behandlung von COVID-19 im Oktober verabreicht wurden.)
Dies ist das zweite Antikörpermedikament, das in diesem Monat für die Notfallzulassung bei COVID-19-Patienten zugelassen wurde, nachdem Eli Lilly am 09.11. von der FDA eine Notfallgenehmigung für Bamlanivimab erhalten hat, eine Behandlung für leichtes bis mittelschweres COVID-19 bei erwachsenen und kindlich und jugendlichen Patienten.
In the thread Trading Regeneron Pharmaceuticals Inc.